Paxlovid

Nirmatrelvir/ritonavir, sold under the brand name Paxlovid, is a co-packaged oral medication, developed by Pfizer and used as a treatment for COVID-19.

Read more in the app

Beyond Paxlovid: Scientists Unveil Game-Changing Antiviral That Could Combat COVID, Ebola, and More

15-day Paxlovid regimen safe but adds no clear long-COVID benefit, trial finds

Scientists Race To Perfect New Oral COVID-19 Treatment Poised To Replace Paxlovid

Paxlovid COVID Treatment Is Most Beneficial for Unvaccinated People with Risk Factors. Others May Not Need It

News at a glance: Giant telescope camera complete, limits to Paxlovid benefits, and missing battlefield bones

Researchers racing to develop Paxlovid replacement

Effectiveness Questioned: Study Finds That Paxlovid Fails To Reduce Long COVID Risk

Paxlovid Cuts Covid Death Risk. But Those Who Need It Are Not Taking It.

Paxlovid treatment does not reduce risk of long COVID, study finds

Why does Paxlovid make things taste bitter?

Covid-19 rebound affects 1 in 5 people after taking Paxlovid

One in five patients experience rebound COVID after taking Paxlovid, new study finds

Saving Lives: Study Finds That Paxlovid Reduces Risk of COVID-19 Hospitalization and Death by 90%

The antiviral drug Paxlovid reduces the risk of getting long COVID